|
Name |
Company |
Description |
|
Phase III |
||
|
Aplidin® (plitidepsin) |
PharmaMar, SA |
Marine-derived antitumor agent being evaluated in combination with dexamethasone (dex) in a trial being conducted in the US, Europe, and Australia LEARN MORE |
|
Carfilzomib (PR-171) |
Onyx Pharmaceuticals |
Proteasome inhibitor being evaluated alone, as part of combination therapy (including with Revlimid-dex in the phase III ASPIRE study, which has completed enrollment), and as frontline or maintenance therapy in early-stage trials LEARN MORE |
|
Denosumab (AMG 162) |
Amgen |
Human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone destruction; under review by the FDA for use in myeloma; approved as Xgeva® for use in bone disease in solid tumors and as Prolia® for osteoporosis in women after menopause |
|
Elotuzumab (HuLuc63; humanized anti-CS1 monoclonal antibody) |
Bristol-Myers Squibb/Abbott |
Monoclonal antibody that binds to CS1, a cell surface protein that is highly expressed on myeloma cells; being evaluated in combination with Revlimid-dex in phase III studies in relapsed and previously untreated patients, as well as alone and with other agents in early-stage trials LEARN MORE |
|
Masitinib (AB1010) |
AB Science |
Oral anticancer agent (tyrosine kinase inhibitor) being evaluated in combination with Velcade-dex in a phase III study being conducted in the US and Europe |
|
Panobinostat (LBH589) |
Novartis |
Deacetylase (DAC) inhibitor; being evaluated in combination with other agents, including Velcade-dex in a phase III study LEARN MORE |
|
Perifosine (KRX-0401, D-21266) |
Keryx Biopharmaceuticals, Inc. |
Oral anticancer agent that inhibits cell growth and promotes apoptosis; being evaluated alone and combination with other agents, including Velcade-dex in a phase III study LEARN MORE |
|
Pomalidomide (CC-4047) |
Celgene Corporation |
Type of IMiD™ (immunomodulatory drug) being evaluated alone and in combination with other agents, including a phase III study in combination with dexamethasone LEARN MORE |
|
Zolinza® (vorinostat, SAHA [suberoylanilide hydroxamic acid]) |
Merck |
Histone deacetylase (HDAC) inhibitor, FDA-approved for cutaneous T-cell lymphoma, that has shown activity in relapsed and refractory myeloma; phase III VANTAGE 088 study in combination with Velcade completed, with initial results showing reduced risk of disease progression with the combination over Velcade alone; being evaluated in combination with other agents in early-stage clinical trials LEARN MORE |
|
Phase II |
||
|
AT7519 (AT7519M) |
Astex Therapeutics |
Cyclin-dependent kinase (CDK) inhibitor being evaluated alone and combination with Velcade in a study being facilitated by the MMRC |
|
ARRY-520 |
Array BioPharma |
Agent that inhibits kinesin spindle protein (KSP); being evaluated alone, as well as in combination with Velcade-dex in a study being facilitated by the MMRC |
|
Bexxar® (iodine I 131 tositumomab) |
GlaxoSmithKline |
FDA-approved radiolabeled monoclonal antibody directed against CD20, a marker found on B cells and on some myeloma cells in 13% to 22% of patients |
|
BT-062 |
Biotest AG |
Anti-CD138 monoclonal antibody/cytotoxic agent compound that has demonstrated activity in early testing |
|
CEP-18770 |
Cephalon |
Proteasome inhibitor; being investigated alone and in combination with Revlimid |
|
Dinaciclib (SCH 727965, MK-7965) |
Merck/Ligand Pharmaceuticals |
Cyclin-dependent kinase (CDK) inhibitor |
|
Ibrutinib (PCI-32765) |
Pharmacyclics |
Anticancer agent (Bruton’s tyrosine kinase inhibitor) that targets B cells |
|
Imetelstat (GRN163L) |
Geron Corporation |
Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth |
|
IPH2101 (IPH21, IPH2102) |
Innate Pharma/Bristol-Myers Squibb |
Monoclonal antibody (anti-KIR) that enhances killing of myeloma cells by natural killer (NK) cells; being evaluated alone and in combination with other agents, as well as in smoldering myeloma |
|
KW-2478 |
Kyowa Hakko Kirin Co., Ltd. |
Heat-shock protein (HSP) 90 inhibitor being evaluated in combination with Velcade |
|
Milatuzumab (IMMU-110) and milatuzumab-doxorubicin conjugate (hLL1-DOX) |
Immunomedics |
Humanized monoclonal antibody directed against the CD74 protein found on B cells and myeloma cells; being evaluated as a therapeutic monoclonal antibody and an antibody-drug conjugate |
|
MLN8237 |
Millennium: The Takeda Oncology Company |
Novel agent (Aurora A kinase inhibitor) being evaluated in combination with Velcade in a study being facilitated by the MMRC |
|
MLN9708 |
Millennium: The Takeda Oncology Company |
Oral second-generation proteasome inhibitor; being evaluated alone and in combination with several other agents in relapsed and/or refractory myeloma, and in combination with Revlimid-dex in newly diagnosed disease in a study being facilitated by the MMRC |
|
PD 0332991 |
Pfizer |
Kinase inhibitor being evaluated in combination with Velcade and dexamethasone |
|
TBL-12 |
Unicorn Pacific Corporation |
Sea cucumber extract that displays immunomodulatory properties; being evaluated in untreated, asymptomatic myeloma |
|
Tivantinib (ARQ 197) |
ArQule/National Cancer Institute |
Anti-cancer agent that inhibits an enzyme (c-Met) involved in many cancer cell activities |
|
Treanda® (bendamustine hydrochloride; known as Ribomustin® in Germany) |
Cephalon |
Alkylating agent FDA-approved for use in treating leukemia and lymphoma; approved in Germany for use in myeloma; being evaluated as part of various combination therapies for use in newly diagnosed and relapsed and/or refractory disease, including a study in combination with Revlimid-dex that is being facilitated by the MMRC LEARN MORE |
|
Vidaza® (azacitidine) |
Celgene Corporation |
Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS) being evaluated alone and in combination with other agents |
|
Phase I |
||
|
ACY-1215 |
Acetylon Pharmaceuticals, Inc. |
Oral histone deacetylase (HDAC) inhibitor being evaluated alone and in combination with Velcade |
|
Amrubicin |
Celgene Corporation |
Chemotherapy drug approved in Japan for small-cell lung cancer; being evaluated in combination with Revlimid-dex |
|
BI-505 |
BioInvent International AB |
Monoclonal antibody directed against ICAM-1, a protein that enables immune cells to migrate from the blood into tissues |
|
BMS-833923 |
Bristol-Myers Squibb/Exelixis |
Oral anticancer agent being evaluated alone and in combination with Revlimid-dex or Velcade |
|
BMS-936564 (MDX-1338) |
Bristol-Myers Squibb |
Monoclonal antibody directed against a cell marker (CXCR4) normally found on immune cells and in increased levels in various cancer cells; induces tumor cell apoptosis; being evaluated alone and in combination with Revlimid-dex or Velcade-dex |
|
CX-4945 |
Cylene Pharmaceuticals |
Oral protein kinase (CK2) inhibitor |
|
Daratumumab (HuMax-CD38) |
Genmab |
Human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of myeloma cells |
|
DFRF4539A |
Genentech |
Monoclonal antibody |
|
Folotyn® (pralatrexate) |
Allos Therapeutics |
Chemotherapy drug approved for use in peripheral T-cell lymphoma that is being evaluated in combination with Velcade |
|
Ganetespib (STA-9090) |
Synta Pharmaceuticals |
Synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90); being evaluated with and without Velcade in a trial being facilitated by the MMRC |
|
GDC-0449 |
Genentech |
Synthetic Hedgehog pathway inhibitor |
|
GSK2110183 |
GlaxoSmithKline |
Oral anticancer agent (AKT inhibitor) being evaluated in combination with Velcade-dex in a trial being facilitated by the MMRC |
|
INK128 |
Intellikine |
Oral kinase inhibitor |
|
LGH447 |
Novartis |
Oral anti-cancer agent |
|
Lorvotuzumab mertansine (IMGN901, BB-10901) |
ImmunoGen |
Monoclonal antibody directed against the CD56 marker found on myeloma cells, coupled with a cancer drug; being evaluated in combination with Revlimid-dex |
|
LY2127399 |
Lilly |
Antibody directed against a protein that activates B cells being tested in combination with Velcade |
|
Marizomib (NPI-0052) |
Nereus Pharmaceuticals |
Novel proteasome inhibitor being evaluated in an MMRC-facilitated study that has shown promising early safety data LEARN MORE |
|
MLN4924 |
Millennium: The Takeda Oncology Company |
Novel agent (inhibitor of Nedd8 activating enzyme) |
|
Oncolytic measles virus (MV-NIS) |
Mayo Clinic |
Genetically engineered measles virus being administered with or without cyclophosphamide |
|
SNS01-T |
Senesco Technologies, Inc. |
Anticancer agent targeted to B cells that induces apoptosis |
|
TH-302 |
Threshold Pharmaceuticals |
Anticancer drug that is converted to its active form in areas where there is low oxygen (hypoxia), such as within tumors or in the bone marrow where myeloma cells are found; being evaluated alone and in combination with Velcade |
|
Veliparib (ABT-888) |
Abbott Laboratories |
PARP1 and PARP2 inhibitor |
 |
|
|
|
Corporate Supporters | Terms of Use | Privacy Policy Copyright © 2012 Multiple Myeloma Research Foundation |
